The combination of metformin and sulfonylureas -- Type 2 diabetes drugs -- increased the risk of mortality by 19% and the risk of hospitalization or death because of cardiovascular disease by 43%, researchers found after analyzing nine large observational studies. The experts suggested further studies to evaluate the link between the combination therapy and risk of death as well as "to understand the potential underlying mechanism of its effects."

Full Story:

Related Summaries